IN2012DN01769A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01769A IN2012DN01769A IN1769DEN2012A IN2012DN01769A IN 2012DN01769 A IN2012DN01769 A IN 2012DN01769A IN 1769DEN2012 A IN1769DEN2012 A IN 1769DEN2012A IN 2012DN01769 A IN2012DN01769 A IN 2012DN01769A
- Authority
- IN
- India
- Prior art keywords
- antikine
- mip
- antibodies
- lß7ccl4
- ccl3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23801509P | 2009-08-28 | 2009-08-28 | |
| PCT/US2010/047004 WO2011025962A1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01769A true IN2012DN01769A (enExample) | 2015-06-05 |
Family
ID=43628404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1769DEN2012 IN2012DN01769A (enExample) | 2009-08-28 | 2010-08-27 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8313747B2 (enExample) |
| EP (1) | EP2470671B1 (enExample) |
| JP (2) | JP6109571B2 (enExample) |
| KR (1) | KR101778813B1 (enExample) |
| CN (1) | CN102782148B (enExample) |
| AU (1) | AU2010286516B2 (enExample) |
| BR (1) | BR112012004387A2 (enExample) |
| CA (1) | CA2771781C (enExample) |
| DK (1) | DK2470671T3 (enExample) |
| ES (1) | ES2531561T3 (enExample) |
| HR (1) | HRP20150162T1 (enExample) |
| IN (1) | IN2012DN01769A (enExample) |
| MX (1) | MX2012002427A (enExample) |
| PL (1) | PL2470671T3 (enExample) |
| PT (1) | PT2470671E (enExample) |
| SI (1) | SI2470671T1 (enExample) |
| SM (1) | SMT201500011B (enExample) |
| WO (1) | WO2011025962A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150162T1 (hr) * | 2009-08-28 | 2015-05-08 | Regeneron Pharmaceuticals, Inc. | Antikin antitijela koja se vežu na višestruke cc kemokine |
| WO2012172341A2 (en) * | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating cancer |
| WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
| WO2013036290A1 (en) * | 2011-09-09 | 2013-03-14 | Yale University | Compositions and methods for assessing and treating inflammatory diseases and disorders |
| US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
| TWI612059B (zh) * | 2013-03-15 | 2018-01-21 | 美國禮來大藥廠 | 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體 |
| EA201591993A1 (ru) | 2013-05-23 | 2016-05-31 | Шир Хьюман Дженетик Терапис, Инк. | Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2 |
| JP6220222B2 (ja) * | 2013-10-28 | 2017-10-25 | シスメックス株式会社 | 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品 |
| SG11201604632PA (en) * | 2013-12-09 | 2016-07-28 | Allakos Inc | Anti-siglec-8 antibodies and methods of use thereof |
| JP6825909B2 (ja) | 2014-02-28 | 2021-02-03 | アラコス インコーポレイテッド | シグレック−８関連疾患を処置するための方法および組成物 |
| US10246508B2 (en) * | 2014-03-04 | 2019-04-02 | Chemomab Ltd. | Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines |
| CN104198727A (zh) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法 |
| TWI576112B (zh) * | 2014-10-24 | 2017-04-01 | 國立陽明大學 | 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用以保護胰臟及防止血糖升高的用途 |
| NZ731954A (en) | 2014-12-09 | 2024-11-29 | Regeneron Pharma | Non-human animals having a humanized cluster of differentiation 274 gene |
| WO2016205567A1 (en) | 2015-06-17 | 2016-12-22 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| JP7122002B2 (ja) | 2017-03-01 | 2022-08-19 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
| JP6933724B2 (ja) * | 2017-04-05 | 2021-09-08 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ | Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物 |
| EA201992626A1 (ru) | 2017-05-05 | 2020-04-24 | Аллакос Инк. | Способы и композиции для лечения аллергических заболеваний глаз |
| WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
| US11555074B2 (en) | 2017-10-13 | 2023-01-17 | A & G Pharmaceutical, Inc. | Monoclonal antibodies and conjugates against prostaglandin F2 receptor inhibitor and uses thereof |
| EP3732196A4 (en) * | 2017-12-28 | 2022-01-05 | Astute Medical, Inc. | ANTIBODIES AND ASSAYS FOR CCL14 |
| US12352758B2 (en) | 2018-02-26 | 2025-07-08 | Cornell University | Quantitative biomarkers of EHV-1 susceptibility and protection |
| WO2019217705A1 (en) * | 2018-05-11 | 2019-11-14 | Proplex Technologies, LLC | Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN110117329B (zh) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
| KR102489282B1 (ko) * | 2019-07-02 | 2023-01-17 | 고려대학교 산학협력단 | Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물 |
| EP3994167A4 (en) * | 2019-07-02 | 2023-11-01 | Astute Medical, Inc. | ANTIBODIES AND ASSAY FOR CCL14 |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN113893331B (zh) * | 2020-07-06 | 2024-11-26 | 中国农业科学院特产研究所 | 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用 |
| US20230242623A1 (en) * | 2020-07-08 | 2023-08-03 | Georgia Tech Research Corporation | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection |
| CN116589583A (zh) | 2020-10-16 | 2023-08-15 | 礼新医药科技(上海)有限公司 | 抗ccr8单克隆抗体及其用途 |
| CN115598111B (zh) * | 2021-07-08 | 2025-03-25 | 南京大学 | 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法 |
| CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JPH07509137A (ja) * | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US6316420B1 (en) | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
| US6420346B1 (en) | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| CA2496419A1 (en) | 2002-08-19 | 2004-02-26 | Abgenix, Inc. | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| WO2004050836A2 (en) * | 2002-11-27 | 2004-06-17 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
| CA2590446A1 (en) * | 2004-12-21 | 2006-06-29 | Laboratoires Serono S.A. | Cc-chemokine antagonists |
| WO2009054873A2 (en) * | 2007-08-02 | 2009-04-30 | Novimmune S.A. | Anti-rantes antibodies and methods of use thereof |
| HRP20150162T1 (hr) * | 2009-08-28 | 2015-05-08 | Regeneron Pharmaceuticals, Inc. | Antikin antitijela koja se vežu na višestruke cc kemokine |
-
2010
- 2010-08-27 HR HRP20150162TT patent/HRP20150162T1/hr unknown
- 2010-08-27 SI SI201030901T patent/SI2470671T1/sl unknown
- 2010-08-27 ES ES10812667.3T patent/ES2531561T3/es active Active
- 2010-08-27 DK DK10812667T patent/DK2470671T3/en active
- 2010-08-27 PT PT10812667T patent/PT2470671E/pt unknown
- 2010-08-27 CN CN201080048961.XA patent/CN102782148B/zh not_active Expired - Fee Related
- 2010-08-27 MX MX2012002427A patent/MX2012002427A/es active IP Right Grant
- 2010-08-27 PL PL10812667T patent/PL2470671T3/pl unknown
- 2010-08-27 US US12/870,573 patent/US8313747B2/en active Active
- 2010-08-27 WO PCT/US2010/047004 patent/WO2011025962A1/en not_active Ceased
- 2010-08-27 AU AU2010286516A patent/AU2010286516B2/en active Active
- 2010-08-27 IN IN1769DEN2012 patent/IN2012DN01769A/en unknown
- 2010-08-27 CA CA2771781A patent/CA2771781C/en active Active
- 2010-08-27 BR BR112012004387A patent/BR112012004387A2/pt active Search and Examination
- 2010-08-27 JP JP2012527033A patent/JP6109571B2/ja active Active
- 2010-08-27 EP EP20100812667 patent/EP2470671B1/en active Active
- 2010-08-27 KR KR1020127007885A patent/KR101778813B1/ko not_active Expired - Fee Related
-
2012
- 2012-10-22 US US13/657,120 patent/US9005617B2/en active Active
-
2015
- 2015-01-16 SM SM201500011T patent/SMT201500011B/xx unknown
- 2015-02-24 US US14/630,112 patent/US20150166647A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011829A patent/JP2016135783A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20150162T1 (hr) | 2015-05-08 |
| MX2012002427A (es) | 2012-08-03 |
| EP2470671A1 (en) | 2012-07-04 |
| SMT201500011B (it) | 2015-03-05 |
| US9005617B2 (en) | 2015-04-14 |
| PT2470671E (pt) | 2015-02-05 |
| KR101778813B1 (ko) | 2017-09-14 |
| KR20120091013A (ko) | 2012-08-17 |
| US20150166647A1 (en) | 2015-06-18 |
| JP6109571B2 (ja) | 2017-04-05 |
| US8313747B2 (en) | 2012-11-20 |
| BR112012004387A2 (pt) | 2015-09-08 |
| CA2771781C (en) | 2019-01-15 |
| WO2011025962A1 (en) | 2011-03-03 |
| CN102782148A (zh) | 2012-11-14 |
| RU2012111820A (ru) | 2013-10-10 |
| US20130108640A1 (en) | 2013-05-02 |
| EP2470671A4 (en) | 2013-04-03 |
| PL2470671T3 (pl) | 2015-05-29 |
| ES2531561T3 (es) | 2015-03-17 |
| DK2470671T3 (en) | 2015-02-09 |
| JP2016135783A (ja) | 2016-07-28 |
| JP2013503192A (ja) | 2013-01-31 |
| AU2010286516B2 (en) | 2016-10-06 |
| US20110059107A1 (en) | 2011-03-10 |
| CN102782148B (zh) | 2016-04-20 |
| CA2771781A1 (en) | 2011-03-03 |
| EP2470671B1 (en) | 2014-12-24 |
| SI2470671T1 (sl) | 2015-04-30 |
| AU2010286516A2 (en) | 2012-06-14 |
| AU2010286516A1 (en) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01769A (enExample) | ||
| EP4477668A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| TN2014000107A1 (en) | Anti-aplhabetatcr antibody | |
| MX2010007935A (es) | Anticuerpo monoclonal humanizado anti-nkg2a humano. | |
| AU2018200640B2 (en) | Humanization of rabbit antibodies using a universal antibody framework | |
| WO2010039900A3 (en) | Non-human mammals for the production of chimeric antibodies | |
| DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
| MX2012000841A (es) | Optimizacion de la produccion de anticuerpos. | |
| PH12019502730A1 (en) | Method of manufacturing bispecific antibodies and therapeutic use of such antibodies | |
| CR20190009A (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso. | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| MX2013003182A (es) | Purificacion de anticuerpos por cromatografia de lecho movil simulada. | |
| MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
| MX337684B (es) | Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f. | |
| NZ714079A (en) | Purification process for monoclonal antibodies | |
| NZ592036A (en) | Methods for producing antibodies from plasma cells | |
| NZ594339A (en) | Anti-fgfr3 antibodies and methods using same | |
| WO2009130459A3 (en) | Epitopes of il-17a and il-17f and antibodies specific thereto | |
| MX366112B (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
| MX337203B (es) | Novedosas moleculas inhbidoras de jnk. | |
| UA105405C2 (ru) | Гуманизированное антитело против человеческого il-22ra | |
| HK1209133A1 (en) | Process for reducing antibody aggregate levels and antibodies produced thereby | |
| PL2099812T3 (pl) | Sposób wytwarzania tagatozy z wykorzystaniem izomeryzacji galaktozy o wysokiej wydajności | |
| WO2012122513A3 (en) | Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution | |
| WO2013186630A3 (en) | Humanized antibodies to ca215 |